Skip to content
Phytonadione
Aquamephyton, Konakion, M.v.i, Mephyton, Vitamin K1, Vitaped (phytonadione) is a small molecule pharmaceutical. Phytonadione was first approved as Mephyton on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Phytonadione
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
Tradename
Company
Number
Date
Products
M.V.I. PEDIATRICHospiraN-018920 DISCN2000-09-21
1 products, RLD
Hide discontinued
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pantothenic acid
+
Phytonadione
+
Pyridoxine
+
Riboflavin
+
Thiamine
+
Vitamin a palmitate
+
Vitamin e
Tradename
Company
Number
Date
Products
VITAPEDHospiraN-020176 DISCN1993-12-29
1 products
Hide discontinued
Phytonadione
Tradename
Company
Number
Date
Products
MEPHYTONBausch Health CompaniesN-010104 DISCN1982-01-01
1 products, RLD
AQUAMEPHYTONPAI PharmaN-012223 DISCN1982-01-01
2 products, RLD
KONAKIONRocheN-011745 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
adult infuvite multiple vitaminsNew Drug Application2016-10-28
mephytonNew Drug Application2020-11-17
phytonadioneANDA2022-12-29
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B02: Antihemorrhagics
— B02B: Vitamin k and other hemostatics
— B02BA: Vitamin k containing hemostatics
— B02BA01: Phytomenadione
HCPCS
Code
Description
J3430
Injection, phytonadione (vitamin k), per 1 mg
Clinical
Clinical Trials
253 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—11—11619
ObesityD009765EFO_0001073E66.92——11013
Liver cirrhosisD008103EFO_0001422K74.0—113712
Hepatic encephalopathyD006501K72.912——248
Type 2 diabetes mellitusD003924EFO_0001360E11———156
Muscular atrophyD009133HP_0003202—1—124
PhenylketonuriasD010661E70.0———123
InflammationD007249———123
Colorectal neoplasmsD015179———112
Iron-deficiency anemiaD018798HP_0001891D501——1—2
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Milk hypersensitivityD016269EFO_0007369—11—1315
Neuroendocrine tumorsD018358EFO_1001901D3A.8462——10
MalnutritionD044342EFO_0008572E40-E46—11—810
Critical illnessD016638——1—89
Nervous system diseasesD009422G00-G99——1——1
Atopic dermatitisD003876EFO_0000274L20——1——1
EczemaD004485HP_0000964L30.9——1——1
Dental plaqueD003773——1——1
Covid-19D000086382U07.1—11——1
Iron deficienciesD000090463E61.1——1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuroblastomaD009447EFO_0000621—2———2
MedulloblastomaD008527—2———2
MeningiomaD008579EFO_0003098D32.9—2———2
Neuroendocrine carcinomaD01827812———2
OsteoarthritisD010003EFO_0002506M15-M19—1——12
Dental cariesD003731EFO_0003819K02—1——12
Liver neoplasmsD008113EFO_1001513C22.0—1——12
Respiratory insufficiencyD012131HP_0002093J96.9—1——12
OverweightD050177E66.3—1———1
Pancreatic neoplasmsD010190EFO_0003860C2511———1
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcopeniaD055948EFO_1000653M62.842———1113
Insulin resistanceD007333EFO_00026141———23
AgingD000375GO_0007568R41.811———23
Acute-on-chronic liver failureD0652902————2
Pressure ulcerD003668L891————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Metabolic syndromeD024821EFO_0000195E88.81————55
ExerciseD015444EFO_0000483————44
Food hypersensitivityD005512EFO_1001890————44
Weight lossD015431HP_0001824————33
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9————33
Traumatic brain injuriesD000070642S06————33
HyperglycemiaD006943HP_0003074R73.9————22
Ulcerative colitisD003093EFO_0000729K51————22
Oxidative stressD018384EFO_1001905————22
Short bowel syndromeD012778————22
Show 64 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePHYTONADIONE
INNphytomenadione
Description
Phylloquinone is a member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones. It has a role as a cofactor, a plant metabolite and a human metabolite. It is a vitamin K and a member of phylloquinones.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=C(C/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O
Identifiers
PDB—
CAS-ID84-80-0
RxCUI8308
ChEMBL IDCHEMBL1550
ChEBI ID18067
PubChem CID5284607
DrugBankDB01022
UNII IDA034SE7857 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Phytonadione - Amphastar Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,058 documents
View more details
Safety
Black-box Warning
Black-box warning for: Phytonadione
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
192 adverse events reported
View more details